Price
$93.45+2.54%Social Signal Score
Analyst Ratings
51 analysts52-week range
- Last close
- $93.45
- Off 52w high
- -11.3%
- 200-day average
- $89.38
- vs 200-day
- +4.6%
Revenue
$9.76B+32.83%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Geoffrey Straub Martha
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 95,000
- Beta
- 0.57
- Country
- IE
- Piotroski score
- 9 / 9 (Strong)
- Altman Z-score
- 3.14
Financials
Revenue
$9.76B+32.8%Net Income
$1.47B+31.8%EBITDA
$2.68B+21.6%Free Cash Flow
$1.29B+7.1%EPS (diluted)
$1.14+42.5%Shares Outstanding (diluted)
1.29B-7.7%Operating Expenses
$3.97BCash & Debt
$8.82BReturn of Capital
$1.19BRevenue by Segment (annual)
$36.19BDividend per Share
$0.72Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $36.36B | $4.80B | $3.75 |
| 2025 | $33.54B | $4.66B | $3.63 |
| 2024 | $32.36B | $3.68B | $2.77 |
| 2023 | $31.23B | $3.76B | $2.83 |
| 2022 | $31.69B | $5.04B | $3.75 |
| 2021 | $30.12B | $3.61B | $2.68 |
| 2020 | $28.91B | $4.79B | $3.57 |
| 2019 | $30.56B | $4.63B | $3.44 |
| 2018 | $29.95B | $3.10B | $2.29 |
| 2017 | $29.71B | $4.03B | $2.92 |
| 2016 | $28.83B | $3.54B | $2.51 |
| 2015 | $20.26B | $2.67B | $2.44 |
| 2014 | $17.00B | $3.06B | $3.06 |
| 2013 | $16.59B | $3.47B | $3.40 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MDT's reported EPS growth of 0.8% a year over 13 years.
- EPS in 5 years
- $3.90
- Implied price
- $85.73
- Return from $100.61
- -3.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $42.62 — -57.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| -9.2% | -18.1% | -15.3% | -12.8% | -10.5% | -8.4% |
| -4.2% | -13.6% | -10.6% | -8.0% | -5.6% | -3.4% |
| 0.8% | -9.1% | -5.9% | -3.1% | -0.6% | 1.6% |
| 5.8% | -4.6% | -1.3% | 1.7% | 4.3% | 6.7% |
| 10.8% | -0.1% | 3.4% | 6.5% | 9.2% | 11.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70-12.50%Social Signal Score
Mentions (78)
- Newsfool.com·1d ago·Positive
Medtronic Is About to Report Its First Earnings Since Spinning Off MiniMed. Should You Buy the Stock Before Nov. 24? Medtronic concluded its spin-off of MiniMed in October. Investors will expect rising sales and stabilizing margins in its upcoming report.
View source ↗ - Newszacks.com·3d ago·Neutral
Ahead of Medtronic (MDT) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Medtronic (MDT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended October 2026.
View source ↗ - Newszacks.com·4d ago·Neutral
Medtronic (MDT) Declines More Than Market: Some Information for Investors Medtronic (MDT) closed the most recent trading day at $100.72, moving 1.56% from the previous trading session.
View source ↗ - Newszacks.com·4d ago·Neutral
Should You Continue to Hold Medtronic Stock in Your Portfolio? MDT's growth prospects gain momentum from Hugo adoption, international expansion and Neuroscience advances, despite margin and currency headwinds.
View source ↗ - Newszacks.com·5d ago·Neutral
Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
View source ↗ - Newszacks.com·5d ago·Positive
MDT Q2 Earnings Preview: Will Cardiovascular Performance Lift Results? Medtronic's Q2 results may benefit from strong Cardiovascular performance, led by cardiac ablation momentum, while Neuroscience and Diabetes add growth.
View source ↗ - Newsprnewswire.com·5d ago·Negative
…ends the Hugo™ RAS system's reach into one of the fastest-growing areas of U.S. robotic surgery. GALWAY, Ireland, Nov. 17, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) has cleared the Hugo™ robotic-assisted surgery (RAS) system for use in general surgery procedures.
View source ↗ - Newszacks.com·12d ago·Neutral
Medtronic (MDT) Dips More Than Broader Market: What You Should Know The latest trading day saw Medtronic (MDT) settling at $101.6, representing a -1.16% change from its previous close.
View source ↗ - Newszacks.com·20d ago·Negative
Medtronic (MDT) Ascends While Market Falls: Some Facts to Note Medtronic (MDT) reached $99.36 at the closing of the latest trading day, reflecting a +2.92% change compared to its last close.
View source ↗ - Newsfool.com·21d ago·Neutral
Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy? Medtronic recently completed a key spinoff of its diabetes segment. The company is on the cusp of becoming a Dividend King.
View source ↗ - Newszacks.com·24d ago·Neutral
Why the Market Dipped But Medtronic (MDT) Gained Today The latest trading day saw Medtronic (MDT) settling at $97.11, representing a +2.46% change from its previous close.
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Medtronic: Broader Growth, Attractive Valuation Medtronic is rated Buy, trading at a 20.8% P/E discount to sector median, with new products driving broader growth post-MiniMed separation. Pulsed field ablation (PFA) and enabling technologies in Cardiovascular and Spine divisions are key growth engines, with strong Q1 FY2027 results across all segments. Q1 FY2027 organic revenue grew ~7% (adjusted for extra week), but margin expansion remains limited; management is focused on translating growth i
View source ↗ - News247wallst.com·26d ago·Positive
Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks Medtronic's 49-year dividend streak sounds impressive until you meet the two medical device rivals that have been raising payouts even longer, and the differences in yield, valuation, and balance sheet strength could reshape how you think about income investing in
View source ↗ - News247wallst.com·26d ago·Positive
Medtronic Quietly Raised Its Dividend Again. Is It a Buy for Income Investors? Medtronic just extended a nearly half-century dividend streak, but its raise barely outpaces inflation while rivals like Abbott and J&J grow payouts far faster.
View source ↗ - Newsprnewswire.com·31d ago·Positive
…engthen its position in cardiac ablation, building on a legacy of innovation in electrophysiology GALWAY, Ireland, Oct. 22, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive real-world registry results for the Affera™ Mapping and Ablation System with the Sphere-9™ Catheter and the PulseSelect™ Pulsed Field Ablation (PFA) System. The global registry analyses, presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 scientific…
View source ↗ - Newszacks.com·34d ago·Positive
Medtronic (MDT) Stock Dips While Market Gains: Key Facts In the latest trading session, Medtronic (MDT) closed at $92.77, marking a -2.09% move from the previous day.
View source ↗ - Newszacks.com·37d ago·Neutral
Is it Apt to Retain Medtronic Stock in Your Portfolio Now? MDT expands in cardiac ablation, robotics, hypertension and digital surgery, but tariff, inflation and currency risks are likely to pressure margins.
View source ↗ - Newsprnewswire.com·38d ago·Positive
…™* multi-parameter wearable Annual list recognizes inventions making the world better and smarter GALWAY, Ireland, Oct. 15, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Stealth AXiS™ surgical system and the Corsano™* multi-parameter wearable have been named to the TIME Best Inventions of 2026 list. The annual award highlights the most impactful new products and ideas of the year, assessed by TIME editors.
View source ↗ - News247wallst.com·39d ago·Neutral
Medtronic Pays More Today. Abbott Raises Its Dividend Faster. Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choosing the wrong one in retirement could cost you more than you expect.
View source ↗ - Newsprnewswire.com·39d ago·Neutral
Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer GALWAY, Ireland, Oct. 14, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced the final results of its previously announced offer to exchange shares of common stock of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED) for outstanding Medtronic ordinary shares at an exchange ratio determined by a formula described in a registration statement filed by MiniMed on Form S-4 (Reg No. 333-298914).
View source ↗ - Newszacks.com·40d ago·Neutral
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know Medtronic (MDT) closed at $93.01 in the latest trading session, marking a +1.17% move from the prior day.
View source ↗ - Newsprnewswire.com·41d ago·Negative
Medtronic Announces Preliminary Results of MiniMed Group, Inc. Exchange Offer GALWAY, Ireland, Oct. 12, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced that, based on preliminary results, its previously announced offer to exchange shares of common stock of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED) for outstanding Medtronic ordinary shares was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on October 9, 2026.
View source ↗ - Newsprnewswire.com·46d ago·Neutral
Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc. GALWAY, Ireland, Oct. 7, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced the final exchange ratio for its previously announced offer to exchange outstanding Medtronic ordinary shares for shares of common stock of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED). Medtronic is offering to exchange up to 225,361,295 shares of MiniMed common stock for outstanding Medtronic ordinary shares in t…
View source ↗ - Newsfool.com·46d ago·Positive
The "Trumpflation" Trade Could Get Worse Before It Gets Better. History Says These 2 Stocks Are the Place to Hide. People have long been willing to pay for healthcare despite rising costs, with Medtronic and Eli Lilly offering two different angles on the space.
View source ↗ - News247wallst.com·47d ago·Positive
Better Dividend Play for Retirees: MDT or ABT? One Delivers Significantly More Yield Both Medtronic and Abbott have dropped in 2026, and those declines reshuffled the math on yield, valuation, and long-term growth in ways that push retirement investors toward a clear but maybe surprising choice.
View source ↗ - Newszacks.com·48d ago·Positive
Medtronic (MDT) Outperforms Broader Market: What You Need to Know Medtronic (MDT) concluded the recent trading session at $87.97, signifying a +1.84% move from its prior day's close.
View source ↗ - News247wallst.com·50d ago·Neutral
Medtronic's 49-Year Dividend Streak Faces a New Challenge: Is Growth Finally the Real Story? Medtronic has raised its dividend for 49 straight years while the stock quietly lost a fifth of its value, but something in the operating room just changed the entire conversation about why investors should own it.
View source ↗ - Newsbarrons.com·51d ago·Neutral
Why Medtronic's $4 Billion MiniMed Exchange Offer Is Losing Its Allure The tax-free exchange offer allows Medtronic investors to swap their shares for MiniMed shares held by Medtronic in what Wall Street calls a split-off.
View source ↗ - Newsprnewswire.com·52d ago·Positive
…d physician adoption of Medtronic solutions addressing urge urinary incontinence and hypertension GALWAY, Ireland, Oct. 1, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the American Medical Association (AMA) approved new Category I Current Procedural Terminology (CPT®) codes for two of its technologies, which represent important long-term growth opportunities for Medtronic: Altaviva™ implantable tibial neuromodulation device for t…
View source ↗ - Newszacks.com·52d ago·Neutral
Why Is Medtronic (MDT) Down 6.4% Since Last Earnings Report? Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsfool.com·52d ago·Positive
History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade. Johnson & Johnson has significantly outperformed Medtronic over the past decade. Much of its outperformance started with its 2021 decision to spin off its consumer healthcare business.
View source ↗ - Newszacks.com·54d ago·Negative
Medtronic (MDT) Registers a Bigger Fall Than the Market: Important Facts to Note In the closing of the recent trading day, Medtronic (MDT) stood at $87.09, denoting a -2.69% move from the preceding trading day.
View source ↗ - Newsfool.com·56d ago·Positive
Medtronic's High Dividend Yield Gets Little Attention on Wall Street -- Should You Buy the Stock Anyway? At the current share price, Medtronic's dividend yield is 3.2%. The company has increased its payouts for 49 consecutive years.
View source ↗ - Newszacks.com·60d ago·Negative
Here's Why Medtronic (MDT) Fell More Than Broader Market Medtronic (MDT) reached $89.3 at the closing of the latest trading day, reflecting a -1.62% change compared to its last close.
View source ↗ - Newsseekingalpha.com·60d ago·Positive
Medtronic: Buy The 3% Yield And Strong Free Cash Flow Growth Medtronic is initiated with a buy rating and a $106.33 price target, implying 17% upside and a 3% dividend yield. Q1 FY27 results exceeded expectations, with normalized revenue growth of 7% and notable strength in Cardiovascular and Neuroscience segments. Guidance was raised for revenue and EPS, but margin expansion is expected to materialize gradually as product mix shifts toward higher-margin recurring revenues.
View source ↗ - Newsseekingalpha.com·60d ago·Negative
Medtronic: The Turnaround Is No Longer Quiet Medtronic delivered solid Q1 FY27 results, with organic revenue growth of ~7%, and raised full-year guidance to 7.25–7.75%. Newer businesses, especially Cardiac Ablation Solutions, are now meaningful contributors, supporting a more robust growth profile for MDT. The MiniMed separation will make MDT smaller but more profitable, with expected margin improvements and a sharper focus on core segments.
View source ↗ - Newsseekingalpha.com·61d ago·Positive
Medtronic: Don't Miss Out On This Dividend Aristocrat Deal Now Medtronic has trounced the S&P 500 index in recent months. The company's strong showing in Q1 2027 prompted it to raise its non-GAAP EPS guidance for FY 2027. Medtronic's interest coverage ratio and net debt to EBITDA ratio are both healthy.
View source ↗ - Newsglobenewswire.com·67d ago·Neutral
Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies
View source ↗ - Newsprnewswire.com·67d ago·Negative
…in more than 45 million procedures worldwide is now cleared for robotic-assisted surgery in the U.S. GALWAY, Ireland, Sept. 16, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) has cleared the LigaSure™ RAS Maryland jaw device for use with the Hugo™ robotic-assisted surgery (RAS) system.
View source ↗ - Newsmarketbeat.com·68d ago·Neutral
Medtronic Sees AI, Ablation and Targeted M&A Fueling Growth Medtronic NYSE: MDT Chief Financial Officer Thierry Piéton said the medical-device maker's focus on acute procedures, expanding innovation pipeline and increased use of targeted acquisitions are supporting its recent growth momentum.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Medtronic plc (MDT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Medtronic plc (MDT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·69d ago·Positive
…s with option for a generally tax-free exchange for U.S. federal income tax purposes GALWAY, Ireland, Sept. 14, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced that it has commenced an exchange offer to split off at least 80.1% of the shares of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED).
View source ↗ - Newsprnewswire.com·69d ago·Negative
…t it has filed a Form S-4 Registration Statement today with the Securities and Exchange Commission (the "SEC") in connection with Medtronic plc's ("Medtronic"; NYSE: MDT) offer to exchange up to 225,361,295 shares of MiniMed common stock, representing 80.1% of the total outstanding shares of MiniMed common stock, for outstanding Medtronic ordinary shares that are validly tendered and not validly withdrawn.
View source ↗ - News247wallst.com·70d ago·Positive
Two Medical Device Dividend Giants, One Better Buy: Medtronic vs. Abbott Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one.
View source ↗ - Newszacks.com·74d ago·Positive
Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum MDT lifts its 2027 outlook as broad-based growth accelerates, but margin pressure and competition could test momentum.
View source ↗ - Newsmarketbeat.com·74d ago·Neutral
Medtronic Touts AI, Robotics and Ablation Growth at Wells Fargo Conference Medtronic NYSE: MDT executives said the medical device maker is seeing accelerating growth across major franchises and emerging product categories, supported by innovation in artificial intelligence, robotics and new therapies.
View source ↗ - Newszacks.com·75d ago·Positive
Is Medtronic Worth Buying as Growth Improves but Risks Stay Elevated? MDT's stronger growth and earnings outlook improve its case, but margin, currency and execution risks keep investors selective.
View source ↗ - Newszacks.com·80d ago·Positive
Why Medtronic (MDT) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·81d ago·Neutral
MDT Q1 Earnings Call Focuses on Broad Growth, Raised Guidance Medtronic raises its fiscal 2027 outlook as growth broadens across major franchises and newer platforms, with robotics and ablation investments advancing.
View source ↗ - Newszacks.com·81d ago·Positive
Why Medtronic (MDT) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newsbenzinga.com·81d ago·Positive
Medtronic Analysts Raise Their Forecasts After Upbeat Q1 Earnings Medtronic PLC (NYSE:MDT) on Tuesday reported better-than-expected first-quarter financial results and raised its FY27 adjusted EPS guidance.
View source ↗ - Newsprnewswire.com·81d ago·Neutral
Cornerstone Robotics ogłasza strategiczne partnerstwo z Medtronic mające na celu zwiększenie dostępu do chirurgii robotycznej na świecie /PRNewswire/ -- Cornerstone Robotics, innowacyjna firma z branży robotyki chirurgicznej założona i mająca siedzibę w Hongkongu, ogłosiła dziś strategiczne
View source ↗ - Newsyoutube.com·82d ago·Positive
Medtronic CEO Martha on beating estimates in Q1: Driven by growth across many of our businesses Geoff Martha, Medtronic CEO, joins 'Squawk on the Street' to discuss shares rising Tuesday after the company announced a $700 million investment in Cornerstone Robotics, a robotic surgical company.
View source ↗ - Newsseekingalpha.com·82d ago·Positive
Medtronic plc (MDT) Q1 2027 Earnings Call Transcript Medtronic plc (MDT) Q1 2027 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·82d ago·Positive
Medtronic's Stars Are Aligning for a Price Recovery Medtronic NYSE: MDT is a good buy in late 2026 because stars such as value, growth, guidance, partnerships, and dividends are aligning. They point to sustained outperformance and potential acceleration but, more importantly, to robust capital returns.
View source ↗ - Newszacks.com·82d ago·Positive
Medtronic Q1 Earnings & Revenues Top Estimates, Stock Up in Pre-Market MDT beats Q1 earnings and revenue estimates as broad-based growth drives shares higher and prompts a fiscal 2027 guidance boost.
View source ↗ - Newszacks.com·82d ago·Neutral
Here's What Key Metrics Tell Us About Medtronic (MDT) Q1 Earnings Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsmarketbeat.com·82d ago·Neutral
Medtronic Q1 Earnings Call Highlights Medtronic NYSE: MDT reported fiscal 2027 first-quarter revenue of $9.8 billion and adjusted earnings per share of $1.45, as the medical-device maker cited broad-based demand, commercial execution and momentum in several growth platforms.
View source ↗ - Newswsj.com·82d ago·Neutral
Medtronic Lifts Outlook, Invests Over $700 Million in Heart Tech & Robotics Medtronic raised its outlook for the year after posting higher fiscal first-quarter profit and sales, driven by broad-based demand and contributions from newer growth platforms.
View source ↗ - Newsbarrons.com·82d ago·Neutral
Medtronic Stock Rises on Better-Than-Expected Earnings and $700 Million Investment in a Robot Surgeon Medtronic stock advances after the company posts better-than-expected quarterly earnings, raises revenue guidance, and announces a $700 million investment.
View source ↗ - Newsprnewswire.com·82d ago·Positive
…s, new growth platforms, and recent portfolio investments support the long-term growth trajectory GALWAY, Ireland, Sept. 1, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2027 (FY27), which ended July 31, 2026.
View source ↗ - Newsprnewswire.com·82d ago·Neutral
Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR GALWAY, Ireland and REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, and Pi-Cardia Ltd.
View source ↗ - Newsbenzinga.com·82d ago·Neutral
Medtronic, Dell and 3 Stocks to Watch Heading Into Tuesday With U.S. stock futures trading slightly lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
View source ↗ - Newszacks.com·83d ago·Neutral
Brokers Suggest Investing in Medtronic (MDT): Read This Before Placing a Bet The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
View source ↗ - Newsbenzinga.com·86d ago·Neutral
Medtronic Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Medtronic plc (NYSE:MDT) will release its first earnings report before the opening bell on Tuesday, Sept. 1.
View source ↗ - Newszacks.com·87d ago·Positive
Is This the Right Time to Hold Medtronic Stock in Your Portfolio? MDT's Cardiovascular gains and renal denervation growth offer upside, but tariffs and currency headwinds cloud its outlook.
View source ↗ - Newszacks.com·87d ago·Neutral
Insights Into Medtronic (MDT) Q1: Wall Street Projections for Key Metrics Beyond analysts' top-and-bottom-line estimates for Medtronic (MDT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2026.
View source ↗ - Newszacks.com·88d ago·Positive
MDT's Q1 Earnings on Deck: How Should You Play the Stock Now? Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.
View source ↗ - Newszacks.com·89d ago·Positive
Medtronic (MDT) Stock Dips While Market Gains: Key Facts In the latest trading session, Medtronic (MDT) closed at $91.22, marking a -1.81% move from the previous day.
View source ↗ - Newsseekingalpha.com·92d ago·Neutral
Medtronic: The CAS Catalyst Can Close A 27% Peer Discount Medtronic is rated a 'Buy,' favored for its attractive valuation and potential upside from its CAS segment despite recent underperformance. CAS, now 5-6% of revenue, is annualizing above $2B and could reach $3B in a few years if execution remains strong. Guidance targets 6.75%-7.25% organic growth and $5.90-$6.00 EPS, but calendar effects and MiniMed separation timing are key variables.
View source ↗ - Newsprnewswire.com·94d ago·Neutral
Medtronic announces cash dividend for second quarter of fiscal year 2027 GALWAY, Ireland, Aug. 20, 2026 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 20, 2026, approved the company's cash dividend for the second quarter of fiscal year 2027 of $0.72 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in June 2026.
View source ↗ - Newsseekingalpha.com·94d ago·Positive
Medtronic: Expecting Strong Revenue Growth In Fiscal Q1 Medtronic is reiterated as a "Buy," with shares offering over 10% fundamental upside and attractive valuation metrics. Q4 delivered 6.6% organic revenue growth—best in a decade—driven by double-digit gains in the Cardiovascular and Diabetes segments. FY 2027 guidance targets 6.75%-7.25% organic revenue growth and $5.90-$6.00 non-GAAP EPS, despite tariff and competitive headwinds.
View source ↗ - Newszacks.com·96d ago·Neutral
Medtronic (MDT) Advances While Market Declines: Some Information for Investors In the most recent trading session, Medtronic (MDT) closed at $92.09, indicating a +1.64% shift from the previous trading day.
View source ↗ - Newszacks.com·96d ago·Positive
MDT vs. A: Which Stock Should Value Investors Buy Now? Investors looking for stocks in the Medical - Products sector might want to consider either Medtronic (MDT) or Agilent Technologies (A). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newszacks.com·101d ago·Neutral
Wall Street Bulls Look Optimistic About Medtronic (MDT): Should You Buy? The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
View source ↗ - Newszacks.com·104d ago·Negative
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know In the closing of the recent trading day, Medtronic (MDT) stood at $89.41, denoting a +2.58% move from the preceding trading day.
View source ↗ - Newsseekingalpha.com·104d ago·Positive
Medtronic: Buy This Undervalued Dividend Aristocrat Before The Market Catches On Medtronic is rated 'Buy' for its compelling combination of income, growth, and value. MDT's growth is led by cardiac ablation with 124% U.S. segment growth and rapid expansion of the Hugo robotic surgery platform. Management guides for 11.75% organic revenue growth in Q1 2027, with CAS expected to outpace the market and Symplicity renal denervation gaining traction.
View source ↗ - Newsfool.com·106d ago·Positive
Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now? Medtronic has launched new devices that will help further improve its financial results. Intuitive Surgical's latest da Vinci system could expand its addressable market.
View source ↗
Earnings
Tue, Nov 24(tomorrow)
Consensus estimate $1.33 per share
Typical surprise +2.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Sep 1$1.45 vs $1.39beat
- Wed, Jun 3$1.55 vs $1.54beat
- Tue, Feb 17$1.36 vs $1.34beat
- Tue, Nov 18$1.36 vs $1.31beat
- Tue, Aug 19$1.26 vs $1.23beat
- Wed, May 21$1.62 vs $1.58beat
Estimates and results for MDT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MDT officers and directors.
- Bought
- —
- Sold
- $6.5m
0 trades
6 trades
- Marinaro Michaelsold
- Martha Geoffreysold
- Kiil Harry Skipsold
- Walter Matthew R.sold
- Kiil Harry Skipsold
- Kiil Harry Skipsold
94 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (28d later)Buy$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Sep 2, 2026 (9d later)Sell$15,001 - $50,000
- Rich McCormickhouse · GA06 · disclosed Aug 17, 2026 (18d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Aug 6, 2026 (456d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (709d later)Sell$15,001 - $50,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 9, 2026 (25d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Apr 6, 2026 (17d later)Sell$15,001 - $50,000
- Julie Johnsonhouse · TX32 · disclosed Jan 16, 2026 (29d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Dec 12, 2025 (29d later)Sell$1,001 - $15,000
- Rich McCormickhouse · GA06 · disclosed Dec 10, 2025 (35d later)Buy$1,001 - $15,000
- Rich McCormickhouse · GA06 · disclosed Sep 17, 2025 (917d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Sep 12, 2025 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 10, 2025 (13d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (46d later)Sell$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 2, 2025 (18d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Apr 29, 2025 (21d later)Sell$1,001 - $15,000
- George Whitesideshouse · CA27 · disclosed Apr 23, 2025 (30d later)Sell$50,001 - $100,000
- Bruce Westermanhouse · AR04 · disclosed Apr 17, 2025 (28d later)Sell$1,001 - $15,000
- Bruce Westermanhouse · AR04 · disclosed Apr 17, 2025 (44d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
